Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography

Trial Profile

Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Doxapram (Primary)
  • Indications Hypoxia; Sedation
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 Status changed from not yet recruiting to completed.
    • 18 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 18 Feb 2016 Planned initiation date changed from 1 Oct 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top